Pivotal Bioventure Partners Investment Advisor 13F annual report (2024)
Pivotal Bioventure Partners Investment Advisor is an investment fund managing more than $274 million ran by Robert Hopfner. There are currently 11 companies in Mr. Hopfner’s portfolio. The largest investments include Karuna Therapeutics Inc and Rallybio Corp, together worth $205 million.
$274 million Assets Under Management (AUM)
As of 3rd November 2022, Pivotal Bioventure Partners Investment Advisor’s top holding is 765,895 shares of Karuna Therapeutics Inc currently worth over $172 million and making up 63.0% of the portfolio value.Relative to the number of outstanding shares of Karuna Therapeutics Inc, Pivotal Bioventure Partners Investment Advisor owns more than approximately 0.1% of the company.In addition, the fund holds 2,271,311 shares of Rallybio Corp worth $32.9 million. The third-largest holding is Vaxcyte worth $18.6 million and the next is Akouos worth $12.1 million, with 1,794,088 shares owned.
Currently, Pivotal Bioventure Partners Investment Advisor's portfolio is worth at least $274 million. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Pivotal Bioventure Partners Investment Advisor
The Pivotal Bioventure Partners Investment Advisor office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Robert Hopfner serves as the Managing Partner at Pivotal Bioventure Partners Investment Advisor.
